Feb 4 (Reuters) - Cigna Corp's Express Scripts has settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to ...

Cigna is hoping the settlement it reached with regulators paired with recent legislation will mollify calls to reform PBMs — ...

Cigna Group’s Express Scripts reached a settlement with federal antitrust enforcers to resolve allegations that the company artificially inflated the price of insulin for patients through illegal ...

The Federal Trade Commission on Wednesday finalized a major settlement with Cigna Group’s CI pharmacy benefit manager Express ...

Yet sentiment around the print has cooled recently. EPS estimates have declined 0.17% over the past two months, while revenue estimates have slipped 0.18% over the same period, reflecting mounting ...

Q4 2025 Earnings Call February 5, 2026 8:30 AM ESTCompany ParticipantsRalph Giacobbe - Senior Vice President of Investor ...

The settlement comes after the FTC in September 2024 brought action against three prescription drug benefit managers, including Express Scripts, alleging the companies were artificially inflating the ...

The Federal Trade Commission has announced what it called a “landmark settlement” with Express Scripts over insulin pricing.

The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to ...

Express Scripts’ FTC settlement over insulin pricing is expected to save consumers $7B over 10 years. Read more here.

Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing.